Premium
Review of the Transmission of Hepatitis By Clotting Factor Concentrates
Author(s) -
Tabor E.
Publication year - 1984
Publication title -
scandinavian journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0036-553X
DOI - 10.1111/j.1600-0609.1984.tb02576.x
Subject(s) - clotting factor , medicine , hepatitis , hepatitis b , immunology , virology , liver disease , chronic hepatitis , hepatitis a , transmission (telecommunications) , virus , gastroenterology , electrical engineering , engineering
Hepatitis remains a serious complication of the treatment of hemophilia. Even the most sensitive assays for the hepatitis B surface antigen cannot detect every plasma unit which contains the hepatitis B virus. Some (but not all) lots of clotting factor concentrates manufactured from plasma screened for hepatitis B surface antigen have been documented to transmit hepatitis B. Chronic hepatitis B results from between 7–11 percent of hepatitis B infections in hemophiliacs; associated severe chronic liver damage has been documented in 2 percent of infections. Delta agent infection accompanying hepatitis B infection appears to be responsible for significant liver disease in some hemophiliacs. In contrast, nearly every lot of clotting factor concentrate transmits one or more agents of non‐A, non‐B hepatitis. Chronic non‐A, non‐B hepatitis appears to result from nearly 50 percent of acute infections. Although liver damage accompanies most of these chronic cases, recent studies have suggested that partial resolution of histologic abnormalities may occur spontaneously in some hemophiliacs.